> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# RTW Funds Hold 5.6% Of Larimar As The Drugmaker Seeks Accelerated Approval
- URL: https://www.bullished.co/rtw-funds-hold-5-6-of-larimar-as-the-drugmaker-seeks-accelerated-approval-201c0e5f/
- Published: 2026-11-16T13:41:30.000Z
- Updated: 2026-11-16T13:41:30.000Z
- Description: Larimar's projected cash runway extends into late second quarter 2027, before its anticipated mid-2027 U.S. approval.
- Author: Matteo Parrino
- Tags: SEC Filings, LRMR, Industry: Healthcare

RTW Investments reported Monday that funds it advises held a [5.6% stake](https://www.sec.gov/Archives/edgar/data/0001493215/000149321526000194/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Larimar Therapeutics](https://www.bullished.co/tag/lrmr/), which develops experimental treatments for complex rare diseases. The passive ownership disclosure covers September 30 holdings; Larimar separately said Monday it completed its accelerated-approval application for its main drug candidate, nomlabofusp.

## One Fund Position, Shared Authority

The RTW funds directly held 5,820,891 common shares. Roderick Wong, RTW Investments' managing partner and chief investment officer, reported the same holding alongside the adviser.

RTW and Wong have [shared voting authority](https://www.sec.gov/Archives/edgar/data/0001493215/000149321526000194/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) and shared power to sell the position. The funds are entitled to dividends and sale proceeds.

Both reporting parties certified that the shares were acquired and held in ordinary business activity, without seeking to change or influence Larimar's control.

## Nomlabofusp Moves Toward FDA Review

Larimar said in its Monday business update that it completed its [accelerated-approval application](https://www.globenewswire.com/news-release/2026/11/16/3403379/0/en/larimar-therapeutics-reports-third-quarter-2026-financial-and-business-update.html?ref=bullished.co) for adults and pediatric patients with Friedreich’s ataxia. The genetic disease leaves patients with insufficient frataxin, an essential protein.

Nomlabofusp is an injection under the skin designed to carry frataxin into cells' mitochondria. Larimar's technology aims to transport therapeutic proteins into cells, and substantially all its resources since inception have gone toward nomlabofusp and supporting operations.

Its annual report for the fiscal year ended December 31, 2025 described four completed clinical studies and an ongoing study involving adults and adolescents. Approximately 8,000 doses had been administered across the clinical program.

Larimar said earlier FDA feedback suggested its existing data could support an application and review. The agency also reaffirmed its willingness to consider FXN, or frataxin, as a biological measure that could substitute for clinical outcomes.

## Cash Runway Precedes Approval Target

Larimar had [$128.7 million](https://www.globenewswire.com/news-release/2026/11/16/3403379/0/en/larimar-therapeutics-reports-third-quarter-2026-financial-and-business-update.html?ref=bullished.co) in cash, cash equivalents and marketable securities at September 30\. Management expects that funding to last into late second quarter 2027.

The projected runway ends before the company's anticipated mid-2027 U.S. approval. Larimar targets a third-quarter 2027 launch, contingent on approval.

LRMR's market capitalization was $314 million as of 8:40 a.m. ET Monday.

Larimar expects FDA acceptance of its application in early 2027 and a safety update from its open-label study in the first quarter of 2027.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — RTW Investments, LP re: Larimar Therapeutics, Inc. (LRMR)](https://www.sec.gov/Archives/edgar/data/0001493215/000149321526000194/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99.1 — JOINT FILING AGREEMENT](https://www.sec.gov/Archives/edgar/data/1493215/000149321526000194/ex-99-11162026%5F011121.htm?ref=bullished.co) — SEC EDGAR
- [Larimar Therapeutics Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/16/3403379/0/en/larimar-therapeutics-reports-third-quarter-2026-financial-and-business-update.html?ref=bullished.co) — globenewswire.com

### More on Larimar Therapeutics

- [Larimar Projects Cash Into Late Second Quarter 2027 — Its Conditional Launch Target Comes Later](https://www.bullished.co/larimar-projects-cash-into-late-second-quarter-2027-its-conditional-launch-target-comes-0277007a/)
- [Larimar Seeks Faster FDA Approval For Frataxin Replacement As Confirmatory Testing Continues](https://www.bullished.co/larimar-seeks-faster-fda-approval-for-frataxin-replacement-as-confirmatory-testing-f65d6b2e/)

[All Larimar Therapeutics (LRMR) coverage →](https://www.bullished.co/tag/lrmr/)